Cargando…

Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment

BACKGROUND: Plasma amyloid-β (Aβ) peptides and tau proteins are promising biomarkers of Alzheimer’s disease (AD), not only for predicting Aβ and tau pathology but also for differentiating AD from other neurodegenerative diseases. However, reference intervals for plasma biomarkers of AD in healthy el...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jingshan, Zhao, Xue, Zhang, Wenyan, Zhang, Tianxiang, Wu, Siting, Shao, Jinghao, Shi, Fu-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214719/ https://www.ncbi.nlm.nih.gov/pubmed/37237388 http://dx.doi.org/10.1186/s13195-023-01246-1

Ejemplares similares

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Estimation of Tau and Phosphorylated Tau(181) in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
por: Shekhar, Shashank, et al.
Publicado: (2016)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Plasma phosphorylated tau181 predicts cognitive and functional decline
por: Tropea, Thomas F., et al.
Publicado: (2022)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis
por: Ding, Xulong, et al.
Publicado: (2021)

Association of Nonconcussive Repetitive Head Impacts and Intense Physical Activity With Levels of Phosphorylated Tau(181) and Total Tau in Plasma of Young Elite Soccer Players
por: Cente, Martin, et al.
Publicado: (2023)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
por: Chen, Shi-Dong, et al.
Publicado: (2021)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
por: Qin, Wei, et al.
Publicado: (2022)

Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy
por: Oberstein, Timo Jan, et al.
Publicado: (2022)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
por: Thijssen, Elisabeth H., et al.
Publicado: (2020)

Erratum to: Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Publicado: (2021)

Correlation between cognitive impairment and serum phosphorylated tau181 protein in patients with preeclampsia
por: Wang, Yuanyuan, et al.
Publicado: (2023)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
por: Marksteiner, Josef, et al.
Publicado: (2022)

Usp14 Deficiency Increases Tau Phosphorylation without Altering Tau Degradation or Causing Tau-Dependent Deficits
por: Jin, Youngnam N., et al.
Publicado: (2012)

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
por: Therriault, Joseph, et al.
Publicado: (2022)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction
por: Thanapornsangsuth, Poosanu, et al.
Publicado: (2022)

Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain
por: Horie, Kanta, et al.
Publicado: (2020)

Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients
por: Huang, Yanlu, et al.
Publicado: (2022)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia
por: Luigi, Lorenzini, et al.
Publicado: (2022)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
por: McCollum, Lauren E., et al.
Publicado: (2021)

Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers
por: Kwon, Hyuk Sung, et al.
Publicado: (2023)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Plasma α‐synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson’s disease
por: Ren, Jingru, et al.
Publicado: (2022)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
por: Clark, Christopher, et al.
Publicado: (2021)

Plasma Phosphorylated-tau181 Is a Predictor of Post-stroke Cognitive Impairment: A Longitudinal Study
por: Huang, Li-Kai, et al.
Publicado: (2022)

Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients
por: Traub, Jan, et al.
Publicado: (2022)

In-Cell NMR Study of Tau and MARK2 Phosphorylated Tau
por: Zhang, Shengnan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_20fvjplhk2ldnaebi2v7imq8jj